uniQure to Participate in Multiple Upcoming Industry Conferences in March
March 03 2020 - 7:00AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that it will participate in the following
upcoming conferences in March:
- Cowen 40th Annual Health
Care Conference, March 2 – 4, Boston, MA.• Matt Kapusta,
chief executive officer at uniQure, will be presenting a corporate
update today, March 3, at 9:20 a.m. ET. The live webcast of the
corporate update can be accessed through the link displayed in the
Investor section of the uniQure website. The webcast replay will be
available for at least 72 hours following the live event. Members
of uniQure’s management team also will participate in one-on-one
investor meetings throughout the day.
- Gene Therapy for Blood
Disorders Conference, March 3 – 5, Boston,
MA.• Sander van Deventer, M.D., Ph.D., executive vice
president, research & product development at uniQure, will
present “Evaluating Immunogenic Responses in Systemic
Administration: Determining the ‘Right’ Dose” on Wednesday, March
4, at 3:45 p.m. ET.• Eileen Sawyer, Ph.D., vice president,
global medical affairs of uniQure, will participate in a panel
discussion: “Assessing the Commercial Realities of Launching Gene
Therapies in the Blood Disorder Space”, on Wednesday, March 4, at
9:15 a.m. ET.
- BioCapital Europe by LSP,
March 12, Amsterdam, the Netherlands.• A corporate update
will be presented by Christian Klemt, chief accounting officer of
uniQure, on Thursday, March 12, at 9:30 a.m. CET.
- 2020 Summit Meeting on in
vivo Gene Therapy and Editing Presented by Chardan, March 23 – 24,
Miami, FL.• Sander van Deventer will present on the
Company’s clinical development for hemophilia B on Monday, March
23, at 2:20 p.m. ET, and participate in a panel discussion on AAV
gene therapy March 23 at 3:45 p.m. ET.
- 4th Annual Gene Therapy for
Rare Disorders 2020 Summit, March 30 – April 2, Boston,
MA.• Alex Kuta, Ph.D., executive vice president operations
at uniQure, will present “Extracting Meaningful Data from Clinical
Trials to Present to Regulatory Agencies” on Tuesday, March 31, at
2:30 p.m. ET.
- Clinical Biomarkers &
World CDx Europe 2020 Conference, March 31 – April 1, London,
U.K.• Astrid Valles-Sanchez, Ph.D., senior scientist at
uniQure will be presenting “Translatable Biomarkers in Gene Therapy
for Huntington Disease: Innovative Approaches & Learnings from
Pre-Clinic to the Clinic” on Tuesday, March 31, at 3:30 p.m.
GMT. • In addition, she will participate in the panel
discussion “Precision Medicine Beyond Oncology” on March 31, at
4:30 p.m. GMT.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
hemophilia A, Huntington's disease, Fabry disease, spinocerebellar
ataxia Type 3 and other diseases. www.uniQure.com
uniQure Contacts:
FOR
INVESTORS: |
|
FOR
MEDIA: |
|
|
|
Maria E. Cantor |
Eva M. Mulder |
Tom Malone |
Direct: 339-970-7536 |
Direct: +31 20 240 6103 |
Direct: 339-970-7558 |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Aug 2024 to Sep 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Sep 2023 to Sep 2024